Use of parasitic biological agents for prevention and control of allergic and other IgE-mediated disorders
First Claim
1. A method of treating a disorder characterized by an increase in the level of IgE comprising administering to a mammal in need thereof, a therapeutically effective amount of excretory and secretory products from a helminth.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention describes using, on a repetitive basis, a non-human colonizing helminth compound, in an amount sufficient to establish a transitory parasitic helminth infection and or to simulate in a parasitic helminth infection, thereby having immunosuppressive effect against benign antigens and or stimulating a regulatory immune response characterized by the production of T helper cells 2 (Th2), T regulatory helper cells (TREG) and certain cytokines, including, but not limited to interleukin 10 (IL-10), as a therapy or prophylaxis of allergy and other IgE-mediated disorders, which are marked by an inappropriate IgE immune response including, but not limited to an aberrant and or enhanced IgE antibody production to benign antigens. The invention presents using helminth compound by administering it in a frequency and amount sufficient to eliminate or ameliorate the inappropriate immune response in an asthmatic and or allergic individual.
35 Citations
18 Claims
- 1. A method of treating a disorder characterized by an increase in the level of IgE comprising administering to a mammal in need thereof, a therapeutically effective amount of excretory and secretory products from a helminth.
- 12. A method of treating a disorder characterized by an increase in the level of IgE comprising administering to a mammal in need thereof, a therapeutically effective amount of excretory and secretory products from a helminth, wherein administering the excretory and secretory products stimulates the level of IL-10 in the mammal.
-
17. A method for producing a pharmaceutical composition comprising a helminth parasite preparation comprising the steps of:
-
(1) raising a preparatory animal in a specific human pathogen-free environment;
(2) isolating a helminth parasite from said preparatory animal to form a helminth parasite isolate;
(3) isolating excretory and secretory products from said helminth parasite isolate; and
(3) mixing the excretory and secretory products from step (3) with a pharmaceutically acceptable carrier. - View Dependent Claims (18)
-
Specification